Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
Zacks Investment Research9/24/2026Positive
ILMN
Illumina IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$40.77B
P/E Ratio
46.96
EPS
$5.75
Beta
1.47
52W High
$277.95
52W Low
$88.00
50-Day MA
$209.20
200-Day MA
$158.57
Dividend Yield
—
Profit Margin
18.30%
Forward P/E
40.32
PEG Ratio
3.05
About Illumina Inc
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Fundamentals
| Revenue (TTM) | $4.49B |
| Gross Profit (TTM) | $3.05B |
| EBITDA | $1.16B |
| Operating Margin | 21.10% |
| Return on Equity | 32.30% |
| Return on Assets | 8.67% |
| Revenue/Share (TTM) | $29.57 |
| Book Value | $18.80 |
| Price-to-Book | 13.17 |
| Price-to-Sales (TTM) | 9.07 |
| EV/Revenue | 8.62 |
| EV/EBITDA | 27.96 |
| Quarterly Earnings Growth (YoY) | -9.40% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $151.00M |
| Float | $149.78M |
| % Insiders | 0.21% |
| % Institutions | 106.49% |
Historical Volatility
HV 10-Day
54.53%
HV 20-Day
58.64%
HV 30-Day
54.80%
HV 60-Day
46.92%
HV Rank
88.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($202.65 target)
4
Strong Buy6
Buy6
Hold1
Sell3
Strong SellLatest News
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research9/11/2026Positive
3 Stocks Soon Joining the S&P 500
The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.
Zacks Investment Research9/9/2026Neutral
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Zacks Investment Research9/8/2026Positive
Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock?
Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research9/7/2026Positive
Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
Zacks Investment Research9/4/2026Positive
Should You Add Illumina Stock to Your Portfolio Now?
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
Zacks Investment Research8/28/2026Neutral
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
24/7 Wall Street8/25/2026Positive
BMRN vs. ILMN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks Investment Research8/12/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ILMN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026